RT - Journal
TY - JOUR
A1 - Fawzy, Nagy
A1 - Atia, Hesham
A1 - Galal, Sherif
A1 - Shawky, Jihan
T1 - Prevalence and risk factors of erectile dysfunction among chronic hepatitis C male patients treated with pegylated interferon-α and ribavirin
YR - 2015/1/1
JF - Egyptian Journal of Psychiatry
JO - Egypt J Psychiatr
SP - 40
OP - 44
VO - 36
IS - 1
UL - https://new.ejpsy.eg.net//article.asp?issn=1110-1105;year=2015;volume=36;issue=1;spage=40;epage=44;aulast=Fawzy;t=5
DO - 10.4103/1110-1105.153776
N2 - Aim
The aim of the study was to determine the prevalence and risk factors of erectile dysfunction (ED) among chronic hepatitis C male patients treated with pegylated interferon-α and ribavirin.
Patients and methods
The sample consisted of 85 male patients treated with pegylated interferon-α2a and ribavirin for 12 months, recruited from Tropical and Internal Medicine outpatients of Zagazig University Hospitals. ED was prospectively studied by International Index of Erectile Function questionnaire, depression was assessed by Hospital Anxiety and Depression Scale, and routine laboratory investigations in addition to serum total and free testosterone were evaluated before, during, and 6 months after treatment.
Results
Prevalence of ED among chronic hepatitis C male patients was 40% (34 patients). There was significant deterioration of International Index of Erectile Function scores and Hospital Anxiety and Depression Scale with respect to basal values and a significant decrease in total and free testosterone with gradual improvement toward the end of treatment period. Emotional state and physical profiles were the most significant risk factors for sexual dysfunction.
Conclusion
ED is common among hepatitis C virus patients treated with pegylated interferon-α and ribavirin and it is multifactorial.
ER -